Biodesix, Inc.
BDSX
Rank in Stocks
#20458
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across... Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Share Price
$10.34
Last synced: 2026-11-09
Market Cap
$84.17M
Change (1 day)
21.22%
Change (1 year)
23.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Biodesix, Inc. (BDSX)
Category
Healthcare
Operating Margin for Biodesix, Inc. (BDSX)
Operating Margin as of November 2026 TTM: -20.01%
According to Biodesix, Inc.'s latest financial reports, its current operating margin (TTM) is -20.01%. At the end of 2025 the company had an operating margin of -31.37%.
Operating Margin history for Biodesix, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -20.01% | -36.21% |
| 2025 | -31.37% | -35.15% |
| 2024 | -48.37% | -42.57% |
| 2023 | -84.22% | -36.38% |
| 2022 | -132.39% | 76.26% |
| 2021 | -75.11% | 49.21% |
| 2020 | -50.34% | -53.78% |
| 2019 | -108.92% | -5.14% |
| 2018 | -114.82% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.90% |
US
|
|
| 20.38% | -101.02% |
US
|
|
| 43.02% | -102.15% |
CN
|
|
| 32.03% | -101.60% |
US
|
|
| 22.23% | -101.11% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Biodesix, Inc.'s operating margin
What is Biodesix, Inc.'s operating margin?
Biodesix, Inc.'s operating margin is -20.01%, as of Nov 2026.
What was Biodesix, Inc.'s operating margin in 2025?
In 2025, Biodesix, Inc.'s operating margin was -31.37%, compared with -48.37% in 2024.
How has Biodesix, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Biodesix, Inc.'s operating margin was highest in 2025 (-31.37%) and lowest in 2022 (-132.39%).
How does Biodesix, Inc.'s operating margin compare with similar companies?
Biodesix, Inc.'s operating margin (-20.01%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.